<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00993226</url>
  </required_header>
  <id_info>
    <org_study_id>BU-001-IM</org_study_id>
    <nct_id>NCT00993226</nct_id>
  </id_info>
  <brief_title>An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Undergoing Hysterectomy</brief_title>
  <official_title>An International, Randomised, Double Blinded, Multi-centre, Active- and Placebo-controlled Dose Response Trial to Evaluate the Efficacy and Safety of SABER-Bupivacaine for Postoperative Pain Control in Patients Undergoing Primary, Elective, Open, Abdominal Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Durect</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nycomed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Durect</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to identify the optimal dose of SABER-Bupivacaine for postoperative pain&#xD;
      control in patients undergoing hysterectomy on the basis of pharmacokinetics, efficacy and&#xD;
      safety evaluations. The study duration consists of a screening period up to 14 days and a&#xD;
      treatment period 14 days with a long term follow up visit at 6 months. The study will provide&#xD;
      further data on the efficacy and safety of the product.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity (PI)</measure>
    <time_frame>1 to 72 hours post-surgery</time_frame>
    <description>Pain intensity (PI) on movement AUC over the period 1 to 72 hours post-surgery. Subjects assessed their pain intensity using an 11-point Pain Intensity Numeric Rating Scale (PI-NRS) with NRS scores ranging from 0 (no pain) to 10 (worst pain possible). The AUC is computed for each patient using the standard trapezoidal rule and normalised by dividing by the time interval over which it is computed. This normalisation converts the AUC to the natural pain scale (NRS 0-10) to allow for better translation of the clinical treatment effect magnitude.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Supplemental Opioid Use</measure>
    <time_frame>0-3 days after surgery</time_frame>
    <description>Cumulative IV morphine-equivalent dose of opioid rescue medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First Opioid Rescue Medication Usage</measure>
    <time_frame>0-14 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Related Side Effects</measure>
    <time_frame>0-7 days after surgery</time_frame>
    <description>Opioid-related side effects were recorded 0-7 days after surgery. The Opioid-Related Symptom Distress Scale (OR-SDS) is a composite score computed from a questionnaire containing frequent opioid-related symptoms (Fatigue, Drowsiness, Inability to concentrate, Nausea, Dizziness, Constipation, Itching, Difficulty with urination, Confusion, Retching/vomiting). For each symptom, patients assigned integer scores to assess severity (none=0 to very severe=4), bothersomeness (none=0 to very much=5), and frequency (none=0 to almost constantly=4); patients reported number of Retching/vomiting episodes (none=0, 1-2 episodes=1, 3-4 episodes=2, 5-6 episodes=3, &gt;6 episodes=4).&#xD;
On each day (Day 0-7), the score for each symptom was the mean of the three component scores, and the OR-SDS score was the overall mean of the 10 symptom scores, (values from 0 to 4; larger outcomes are worse). The mean of the daily OR-SDS score from Day 0 to 7 gave the overall OR-SDS Score.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>SABER-Bupivacaine Treatment 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>double-blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SABER-Bupivacaine Treatment 1b</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>double-blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine HCl Treatment 1c</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>double-blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SABER-Bupivacaine Treatment 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>double-blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SABER-Bupivacaine Treatment 2b</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>double-blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine HCl Treatment 2c</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>double-blind</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SABER-Bupivacaine Treatment 1a</intervention_name>
    <description>5.0 ml</description>
    <arm_group_label>SABER-Bupivacaine Treatment 1a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo SABER-Bupivacaine Treatment 1b</intervention_name>
    <description>5.0 ml</description>
    <arm_group_label>Placebo SABER-Bupivacaine Treatment 1b</arm_group_label>
    <other_name>POSIMIR® bupivacaine solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine HCl Treatment 1c</intervention_name>
    <description>40 ml</description>
    <arm_group_label>Bupivacaine HCl Treatment 1c</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SABER-Bupivacaine Treatment 2a</intervention_name>
    <description>7.5 ml</description>
    <arm_group_label>SABER-Bupivacaine Treatment 2a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo SABER-Bupivacaine Treatment 2b</intervention_name>
    <description>7.5 ml</description>
    <arm_group_label>Placebo SABER-Bupivacaine Treatment 2b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine HCl Treatment 2c</intervention_name>
    <description>40 ml</description>
    <arm_group_label>Bupivacaine HCl Treatment 2c</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A planned elective, abdominal hysterectomy&#xD;
&#xD;
          -  Patients suitable for general anaesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known clinically significant hepatic, gastrointestinal, renal, haematological,&#xD;
             urologic, neurological, respiratory, endocrine or cardiovascular system abnormalities&#xD;
&#xD;
          -  Known serious uncontrolled illness: cancer, psychiatric or metabolic disturbances.&#xD;
             History of cured localised malignancies is allowed (i.e. basal or squamous cell skin&#xD;
             carcinoma, breast carcinoma or cervical carcinoma)&#xD;
&#xD;
          -  Abnormal ECG&#xD;
&#xD;
          -  Prolonged QT syndrome&#xD;
&#xD;
          -  Current or regular use of analgesic medication for other indication(s)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nycomed Clinical Trial Operations</last_name>
    <role>Study Chair</role>
    <affiliation>Headquarters</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nycomed</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed</name>
      <address>
        <city>Bayreuth</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed</name>
      <address>
        <city>Békéscsaba</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed</name>
      <address>
        <city>Györ</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed</name>
      <address>
        <city>Nyíregyháza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed</name>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed</name>
      <address>
        <city>Székesfehérvár</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed</name>
      <address>
        <city>Tatabánya</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 9, 2009</study_first_submitted>
  <study_first_submitted_qc>October 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2009</study_first_posted>
  <results_first_submitted>February 24, 2021</results_first_submitted>
  <results_first_submitted_qc>May 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 1, 2021</results_first_posted>
  <disposition_first_submitted>January 23, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>January 23, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 29, 2013</disposition_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postoperative pain</keyword>
  <keyword>Local anaesthesia</keyword>
  <keyword>Postoperative pain after open abdominal hysterectomy surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SABER-Bupivacaine</title>
          <description>5 mL, single dose instilled into surgical incision</description>
        </group>
        <group group_id="P2">
          <title>SABER-placebo</title>
          <description>5 mL, single dose instilled into surgical incision</description>
        </group>
        <group group_id="P3">
          <title>Bupivacaine HCl</title>
          <description>0.25% 40 mL, single dose infiltrated peri-incisionally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SABER-Bupivacaine</title>
          <description>5 mL, single dose instilled into surgical incision</description>
        </group>
        <group group_id="B2">
          <title>SABER-placebo</title>
          <description>5 mL, single dose instilled into surgical incision</description>
        </group>
        <group group_id="B3">
          <title>Bupivacaine HCl</title>
          <description>0.25% 40 mL, single dose infiltrated peri-incisionally</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="27"/>
            <count group_id="B4" value="115"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.7" lower_limit="29" upper_limit="66"/>
                    <measurement group_id="B2" value="44.3" lower_limit="37" upper_limit="53"/>
                    <measurement group_id="B3" value="45.1" lower_limit="35" upper_limit="55"/>
                    <measurement group_id="B4" value="45.8" lower_limit="29" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.1" lower_limit="19.0" upper_limit="33.2"/>
                    <measurement group_id="B2" value="26.2" lower_limit="19.4" upper_limit="34.1"/>
                    <measurement group_id="B3" value="27.0" lower_limit="18.3" upper_limit="35.0"/>
                    <measurement group_id="B4" value="26.4" lower_limit="18.3" upper_limit="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Intensity (PI)</title>
        <description>Pain intensity (PI) on movement AUC over the period 1 to 72 hours post-surgery. Subjects assessed their pain intensity using an 11-point Pain Intensity Numeric Rating Scale (PI-NRS) with NRS scores ranging from 0 (no pain) to 10 (worst pain possible). The AUC is computed for each patient using the standard trapezoidal rule and normalised by dividing by the time interval over which it is computed. This normalisation converts the AUC to the natural pain scale (NRS 0-10) to allow for better translation of the clinical treatment effect magnitude.</description>
        <time_frame>1 to 72 hours post-surgery</time_frame>
        <population>ITT population (patients with data available)</population>
        <group_list>
          <group group_id="O1">
            <title>SABER-Bupivacaine</title>
            <description>5 mL, single dose instilled into surgical incision</description>
          </group>
          <group group_id="O2">
            <title>SABER-placebo</title>
            <description>5 mL, single dose instilled into surgical incision</description>
          </group>
          <group group_id="O3">
            <title>Bupivacaine HCl</title>
            <description>0.25% 40 mL, single dose infiltrated peri-incisionally</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity (PI)</title>
          <description>Pain intensity (PI) on movement AUC over the period 1 to 72 hours post-surgery. Subjects assessed their pain intensity using an 11-point Pain Intensity Numeric Rating Scale (PI-NRS) with NRS scores ranging from 0 (no pain) to 10 (worst pain possible). The AUC is computed for each patient using the standard trapezoidal rule and normalised by dividing by the time interval over which it is computed. This normalisation converts the AUC to the natural pain scale (NRS 0-10) to allow for better translation of the clinical treatment effect magnitude.</description>
          <population>ITT population (patients with data available)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.15" spread="1.74"/>
                    <measurement group_id="O2" value="4.46" spread="1.48"/>
                    <measurement group_id="O3" value="4.27" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Exploratory comparison between SABER-Bupivacaine and Bupivacaine HCl not analyzed inferentially</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.467</p_value>
            <method>t-test in ANOVA model</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.21</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.79</ci_lower_limit>
            <ci_upper_limit>0.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Supplemental Opioid Use</title>
        <description>Cumulative IV morphine-equivalent dose of opioid rescue medication</description>
        <time_frame>0-3 days after surgery</time_frame>
        <population>ITT population (patients with data available)</population>
        <group_list>
          <group group_id="O1">
            <title>SABER-Bupivacaine</title>
            <description>5 mL, single dose instilled into surgical incision</description>
          </group>
          <group group_id="O2">
            <title>SABER-placebo</title>
            <description>5 mL, single dose instilled into surgical incision</description>
          </group>
          <group group_id="O3">
            <title>Bupivacaine HCl</title>
            <description>0.25% 40 mL, single dose infiltrated peri-incisionally</description>
          </group>
        </group_list>
        <measure>
          <title>Supplemental Opioid Use</title>
          <description>Cumulative IV morphine-equivalent dose of opioid rescue medication</description>
          <population>ITT population (patients with data available)</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" spread="24.3"/>
                    <measurement group_id="O2" value="26.3" spread="25.7"/>
                    <measurement group_id="O3" value="23.9" spread="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Exploratory comparison between SABER-Bupivacaine and Bupivacaine HCl not analyzed inferentially</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.331</p_value>
            <method>t-test in ANOVA model</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.51</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.57</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.59</ci_lower_limit>
            <ci_upper_limit>2.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Opioid Rescue Medication Usage</title>
        <time_frame>0-14 days after surgery</time_frame>
        <population>ITT population (patients with data available)</population>
        <group_list>
          <group group_id="O1">
            <title>SABER-Bupivacaine</title>
            <description>5 mL, single dose instilled into surgical incision</description>
          </group>
          <group group_id="O2">
            <title>SABER-placebo</title>
            <description>5 mL, single dose instilled into surgical incision</description>
          </group>
          <group group_id="O3">
            <title>Bupivacaine HCl</title>
            <description>0.25% 40 mL, single dose infiltrated peri-incisionally</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Opioid Rescue Medication Usage</title>
          <population>ITT population (patients with data available)</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.71" spread="45.79"/>
                    <measurement group_id="O2" value="1.53" spread="1.56"/>
                    <measurement group_id="O3" value="87.77" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Related Side Effects</title>
        <description>Opioid-related side effects were recorded 0-7 days after surgery. The Opioid-Related Symptom Distress Scale (OR-SDS) is a composite score computed from a questionnaire containing frequent opioid-related symptoms (Fatigue, Drowsiness, Inability to concentrate, Nausea, Dizziness, Constipation, Itching, Difficulty with urination, Confusion, Retching/vomiting). For each symptom, patients assigned integer scores to assess severity (none=0 to very severe=4), bothersomeness (none=0 to very much=5), and frequency (none=0 to almost constantly=4); patients reported number of Retching/vomiting episodes (none=0, 1-2 episodes=1, 3-4 episodes=2, 5-6 episodes=3, &gt;6 episodes=4).&#xD;
On each day (Day 0-7), the score for each symptom was the mean of the three component scores, and the OR-SDS score was the overall mean of the 10 symptom scores, (values from 0 to 4; larger outcomes are worse). The mean of the daily OR-SDS score from Day 0 to 7 gave the overall OR-SDS Score.</description>
        <time_frame>0-7 days after surgery</time_frame>
        <population>ITT population (patients with data available)</population>
        <group_list>
          <group group_id="O1">
            <title>SABER-Bupivacaine</title>
            <description>5 mL, single dose instilled into surgical incision</description>
          </group>
          <group group_id="O2">
            <title>SABER-placebo</title>
            <description>5 mL, single dose instilled into surgical incision</description>
          </group>
          <group group_id="O3">
            <title>Bupivacaine HCl</title>
            <description>0.25% 40 mL, single dose infiltrated peri-incisionally</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Related Side Effects</title>
          <description>Opioid-related side effects were recorded 0-7 days after surgery. The Opioid-Related Symptom Distress Scale (OR-SDS) is a composite score computed from a questionnaire containing frequent opioid-related symptoms (Fatigue, Drowsiness, Inability to concentrate, Nausea, Dizziness, Constipation, Itching, Difficulty with urination, Confusion, Retching/vomiting). For each symptom, patients assigned integer scores to assess severity (none=0 to very severe=4), bothersomeness (none=0 to very much=5), and frequency (none=0 to almost constantly=4); patients reported number of Retching/vomiting episodes (none=0, 1-2 episodes=1, 3-4 episodes=2, 5-6 episodes=3, &gt;6 episodes=4).&#xD;
On each day (Day 0-7), the score for each symptom was the mean of the three component scores, and the OR-SDS score was the overall mean of the 10 symptom scores, (values from 0 to 4; larger outcomes are worse). The mean of the daily OR-SDS score from Day 0 to 7 gave the overall OR-SDS Score.</description>
          <population>ITT population (patients with data available)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.28"/>
                    <measurement group_id="O2" value="0.34" spread="0.31"/>
                    <measurement group_id="O3" value="0.27" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>SABER-Bupivacaine</title>
          <description>5 mL, single dose instilled into surgical incision</description>
        </group>
        <group group_id="E2">
          <title>SABER-placebo</title>
          <description>5 mL, single dose instilled into surgical incision</description>
        </group>
        <group group_id="E3">
          <title>Bupivacaine HCl</title>
          <description>0.25% 40 mL, single dose infiltrated peri-incisionally</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ECG abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>ECG QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural contusion</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Incision site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>CRP increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Deborah Scott</name_or_title>
      <organization>Durect Corporation</organization>
      <phone>408-777-1417</phone>
      <email>deborah.scott@durect.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

